Related Experiment Videos

Differential inactivation of caspase-8 in lung cancers

Narayan Shivapurkar1, Shinichi Toyooka, Michael T Eby

  • 1Hamon Center for Therapeutic Oncology Research, Departments of Pathology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, Texas 75390-8593, USA.

Cancer Biology & Therapy
|August 13, 2002
PubMed

Insights

Caspase-8 (CASP8) expression is frequently lost in small cell lung carcinoma (SCLC) and carcinoid tumors due to promoter methylation or gene deletion. This loss is not observed in non-small cell lung carcinoma (NSCLC).

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Caspase-8 (CASP8) is a key protease in apoptosis, activated by death receptor signaling.
  • Loss of CASP8 expression has been reported in neuroblastomas via promoter methylation and allelic loss.

Purpose of the Study:

  • To investigate the status of CASP8 gene expression and its inactivation mechanisms in lung tumors and cell lines.
  • To determine if CASP8 functions as a tumor suppressor in neuroendocrine lung tumors.

Main Methods:

  • Reverse transcription-polymerase chain reaction (RT-PCR) to assess gene expression.
  • Western blotting for protein expression analysis.
  • Analysis of promoter methylation and allelic loss using polymorphic markers.

Main Results:

  • CASP8 expression was lost in 79% of small cell lung carcinoma (SCLC) cell lines but retained in all non-SCLC (NSCLC) lines.
  • Promoter methylation was found in 59% of SCLC lines lacking expression, often with biallelic methylation or allele loss.
  • CASP8 promoter methylation was present in 35% of SCLC tumors and 18% of bronchial carcinoid tumors, but not in NSCLC tumors.

Conclusions:

  • CASP8 expression is frequently lost in SCLC and carcinoid tumors, suggesting a role as a tumor suppressor gene in these neuroendocrine lung cancers.
  • Inactivation mechanisms include promoter methylation and potentially gene deletion, but are not observed in NSCLC.
  • The findings highlight CASP8 as a potential therapeutic target in neuroendocrine lung tumors.

Related Concept Videos